Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Research
Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Immunology

Induction of Protective Host Immunity to Carcinoembryonic Antigen (CEA), a Self-Antigen in CEA Transgenic Mice, by Immunizing with a Recombinant Vaccinia-CEA Virus

Erik Kass, Jeffrey Schlom, John Thompson, Fiorella Guadagni, Paolo Graziano and John W. Greiner
Erik Kass
Laboratory of Tumor Immunology and Biology, National Cancer Institute, NIH, Bethesda, Maryland 20892 [E. K., J. S., J. W. G.]; University of Freiburg, Freiburg D-79104, Germany [J. T.]; and Regina Elena Cancer Institute, Rome 00161, Italy [F. G., P. G.]
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeffrey Schlom
Laboratory of Tumor Immunology and Biology, National Cancer Institute, NIH, Bethesda, Maryland 20892 [E. K., J. S., J. W. G.]; University of Freiburg, Freiburg D-79104, Germany [J. T.]; and Regina Elena Cancer Institute, Rome 00161, Italy [F. G., P. G.]
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John Thompson
Laboratory of Tumor Immunology and Biology, National Cancer Institute, NIH, Bethesda, Maryland 20892 [E. K., J. S., J. W. G.]; University of Freiburg, Freiburg D-79104, Germany [J. T.]; and Regina Elena Cancer Institute, Rome 00161, Italy [F. G., P. G.]
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fiorella Guadagni
Laboratory of Tumor Immunology and Biology, National Cancer Institute, NIH, Bethesda, Maryland 20892 [E. K., J. S., J. W. G.]; University of Freiburg, Freiburg D-79104, Germany [J. T.]; and Regina Elena Cancer Institute, Rome 00161, Italy [F. G., P. G.]
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paolo Graziano
Laboratory of Tumor Immunology and Biology, National Cancer Institute, NIH, Bethesda, Maryland 20892 [E. K., J. S., J. W. G.]; University of Freiburg, Freiburg D-79104, Germany [J. T.]; and Regina Elena Cancer Institute, Rome 00161, Italy [F. G., P. G.]
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John W. Greiner
Laboratory of Tumor Immunology and Biology, National Cancer Institute, NIH, Bethesda, Maryland 20892 [E. K., J. S., J. W. G.]; University of Freiburg, Freiburg D-79104, Germany [J. T.]; and Regina Elena Cancer Institute, Rome 00161, Italy [F. G., P. G.]
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published February 1999
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Fig. 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 1.

    Induction of anti-CEA/OVA IgG serum titers in CEA.Tg mice. A, CEA.Tg mice (two mice/group) were given 20 μg of either CEA (▴), OVA (▪), or HBSS (•) in adjuvant twice at 2-week intervals. Two weeks after the final treatment, mice were bled, and serum was tested for the presence of anti-CEA or anti-OVA IgG antibodies as outlined in “Materials and Methods.” Data are the mean ± SE of the A490 nm value for each group. In some cases, the error bars are covered by the symbol. B, in the same experiment, CEA.Tg mice (four mice/group) were given 107 pfu (100 μl; s.c.) of V-Wyeth (▪) or rV-CEA (•). Unimmunized mice (▴) received an equal volume of HBSS. Data are the mean (SE < 10%) A490 nm values for four mice in the HBSS- and V-Wyeth-treated groups. A490 nm values are shown for the four individual rV-CEA-immunized CEA.Tg mice (average of triplicate determinations). Results in A and B are from a representative experiment; two to three experiments were performed for each immunogen with similar outcomes.

  • Fig. 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 2.

    Comparison of anti-CEA IgG responses in CEA.Tg mice and CEA-negative littermates. Groups (four mice/group) of CEA.Tg mice (•) and CEA-negative littermates (▴) were immunized three times (s.c.) with rV-CEA (107 pfu) at 2-week intervals. Serum samples were collected from individual mice 2 weeks after the final immunization and assayed for the presence of anti-CEA IgG antibodies. Results presented are the mean ± SE of the four mice in each group. In some instances, the error bars are covered by the symbol. Data are from a representative experiment that was repeated once with similar results.

  • Fig. 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 3.

    Comparison of CEA-specific CD4+ proliferative responses from CEA.Tg mice (A) and CEA-negative (B) littermates. Mice (two to three mice/group) were given 107 pfu of rV-CEA (▪) or V-Wyeth (▴) by tail scarification (10 μl), whereas control mice (four mice/group) were given an equal volume of HBSS (•). Fourteen days later, mice were sacrificed, spleens were pooled, T cells were isolated, and the proliferative responses to soluble CEA were measured by [3H]thymidine incorporation as described in “Materials and Methods.” Data are presented as the mean ± SE from a representative experiment. The experiment was repeated three to four times with similar results. Note that some error bars are covered by the symbol.

  • Fig. 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 4.

    Splenic CD4+ proliferation following a prime and boost immunization strategy. Groups of CEA.Tg mice (two to three mice/group) were immunized twice with 20 μg of CEA in adjuvant (▴), 107 pfu of V-Wyeth (▪), or 107 pfu of rV-CEA (▵) as described in “Materials and Methods.” Unimmunized CEA.Tg mice received HBSS (•). At sacrifice, spleens from each group were removed and pooled, T cells were isolated, and the lymphoproliferative assay was carried out. The SI was calculated as follows: [cpm (antigen-stimulated cells)]/[cpm (unstimulated cells)]. Each data point represents the mean ± SE of triplicate determinations from a representative experiment; two to three separate experiments were carried out with similar results.

  • Fig. 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 5.

    IFN-γ (▪) and IL-4 (□) production during CEA-mediated CD4+ T-cell proliferation. CEA.Tg mice (two to three mice/group) were immunized with HBSS, CEA, V-Wyeth, or rV-CEA as outlined in the legend of Fig. 4 <$REFLINK> . Spleens were pooled, and T cells were isolated and incubated with freshly isolated, irradiated antigen-presenting cells and 50 μg of CEA for 48 h. Results shown are the mean from triplicate wells (SE ± 15%) from a representative experiment. The experiment was repeated with similar results. No measurable amounts of either IFN-γ and IL-4 were found when splenic T cells from each group were cultured in the absence of CEA. Concanavalin A-stimulated splenic T cells from each group produced approximately 1–2 μg of IFN-γ and 20–30 ng of IL-4/106 cells during the same time period.

  • Fig. 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 6.

    Cytolytic activity of CEA526–533-derived CTLs. The cytolytic activity was tested against EL-4 target cells incubated in the presence of 0.2 μg of CEA526–533. CEA.Tg mice (two mice/group) were previously immunized with HBSS (•), CEA in adjuvant (▴), V-Wyeth (▪), or rV-CEA (▵) as outlined previously. Data presented are the mean ± SE from a representative experiment that was repeated once with similar results.

  • Fig. 7.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 7.

    CEA.Tg mice (•) and CEA-negative littermates (▴) were immunized s.c. with 107 pfu of rV-CEA or V-Wyeth three times at 2-week intervals. Two weeks after the third immunization, all mice were challenged with CEA-expressing tumor cells. Tumor volumes (mm3) for individual mice are shown at 35 days after tumor burden. Tumor-free mice are shown as zero tumor volume. Cumulative data from two independent experiments are presented.

Tables

  • Figures
  • Table 1

    Screening of CEA.Tg micea

    Serum CEA (ng/ml)
    GenotypeNo. of miceRT-PCRaNo. of miceRangeMean ± SE
    CEA.Tg mice25+2512.8–133.060.8 ± 14.9
    CEA-negative littermates25Negb10NegNeg
    Wild-type B6 mice10Neg10NegNeg
    • a Individual mice were bled between 28–35 days. Approximately 100 μl of whole blood were used for PCR-based detection of the CEA transgene. Serum was collected from the remainder and tested for CEA levels as described in “Materials and Methods.”

    • b Neg, <5 ng CEA/ml serum.

  • Table 2

    Analyses of immunoglobulin isotypes in immunized CEA.Tg mice and CEA-negative littermatesa

    Immunoglobulin analysisa
    MiceImmunogenNo. of miceSerum dilutionIgG1IgG2aIgG2bIgG3
    CEA.Tg micerV-CEA110++++++Neg
    210Neg++Neg
    OVA + SDTb150++NegNegNeg
    250++NegNegNeg
    CEA-negative littermatesrV-CEA×41000++++++Neg
    • a Wells in 96-well plates were sensitized with the appropriate immunoglobulin subtype as outlined in “Materials and Methods.” Serum samples from immunized CEA.Tg mice were diluted 1:10 to 1:1250, and the assay was carried out as described. Identification of different immunoglobulin subtypes was based on relative A490 nm using the mean (A490 nm) + 3 SD for the appropriate immunoglobulin subtype as cutoff between negative and positive. For example, wells sensitized with IgG1 and incubated in the presence of serum from nonimmunized CEA.Tg mice had a mean A490 nm + 3 SD of 0.115 + 0.026 = 0.146. Therefore, all IgG-sensitized wells in which the A490 nm was >0.15 were scored +. Moreover, wells in which A490 nm exceeded 0.5 were scored as ++. Data represent the results from duplicate determinations.

    • b SDT, super DETOX adjuvant.

  • Table 3

    Blood chemistries of CEA.Tg mice and CEA-negative littermates immunized with rV-CEAa

    CEA.Tg miceCEA-negative littermates
    MarkerReference (normal) rangeUntreated (n = 3)V-Wyeth (n = 3)rV-CEA (n = 10)UntreatedV-Wyeth (n= 3)rV-CEA (n = 4)
    ASTb72 –288 U/literNormalNormalNormalNot testedNormalNormal
    ALT24 –140 U/literNormalNormalNormalNormalNormal
    Creatine phosphokinase0 –800 U/literNormalNormal↑ (2/10)NormalNormal
    Amylase602 –2311 U/literNormal↑ (3/3)↑ (7/10)↑ (2/3)↑ (4/4)
    BUN9 –28 mg/dlNormalNormalNormalNormalNormal
    Creatinine0.2 –0.7 mg/dlNormalNormalNormalNormalNormal
    Bilirubin (total)0.0 –0.9 mg/dlNormalNormalNormalNormalNormal
    Uric acid2.2 –4.6 mg/dlNormalNormalNormalNormalNormal
    Albumin2.6 –4.6 g/dlNormalNormalNormalNormalNormal
    Protein (total)4.0 –6.2 g/dlNormalNormalNormalNormalNormal
    • a CEA.Tg mice and CEA-negative littermates were immunized and subsequently challenged with CEA-expressing tumor cells as outlined in Fig. 7. <$REFLINK> Blood chemistries were performed on individual mice at approximately 1 month after tumor challenge.

    • b AST, aspartate aminotransferase; ALT, alanine aminotransferase; ↑, elevation in blood markers; (n, n), number of mice with elevated marker, number of mice tested.

  • Table 4

    Analyses of normal tissues from untreated and rV-CEA- and V-Wyeth-treated CEA.Tg micea

    TreatmentNormal tissueHistochemical analysisbCEA expressionc
    UntreatedIntestinal tractNormal+
    Esophagus/stomachNormal+
    KidneysNormal−
    LiverNormal−
    V-WyethIntestinal tractNormal+
    Esophagus/stomachNormal+
    KidneysNormalND
    LiverNormalND
    rV-CEAIntestinal tractNormal+
    Esophagus/stomachNormal+
    KidneysNormal−
    LiverNormalND
    • a Groups of CEA.Tg mice (two mice/group) were treated twice at 2-week intervals with 107 pfu of rV-CEA or V-Wyeth by tail scarification. Two weeks after the second treatment, mice were sacrificed, and spleens were used to generate the data summarized in Fig. 3 <$REFLINK> . Normal tissues were also removed and prepared for immunohistology. Data presented represent the results from both of the CEA.Tg mice in each group.

    • b Routine histological examinations were conducted for each specimen on H&E-stained sections.

    • c CEA expression as indicated by the presence of dark brown DAB cellular precipitate. ND, not done.

PreviousNext
Back to top
February 1999
Volume 59, Issue 3
  • Table of Contents

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Induction of Protective Host Immunity to Carcinoembryonic Antigen (CEA), a Self-Antigen in CEA Transgenic Mice, by Immunizing with a Recombinant Vaccinia-CEA Virus
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Induction of Protective Host Immunity to Carcinoembryonic Antigen (CEA), a Self-Antigen in CEA Transgenic Mice, by Immunizing with a Recombinant Vaccinia-CEA Virus
Erik Kass, Jeffrey Schlom, John Thompson, Fiorella Guadagni, Paolo Graziano and John W. Greiner
Cancer Res February 1 1999 (59) (3) 676-683;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Induction of Protective Host Immunity to Carcinoembryonic Antigen (CEA), a Self-Antigen in CEA Transgenic Mice, by Immunizing with a Recombinant Vaccinia-CEA Virus
Erik Kass, Jeffrey Schlom, John Thompson, Fiorella Guadagni, Paolo Graziano and John W. Greiner
Cancer Res February 1 1999 (59) (3) 676-683;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • INTRODUCTION
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Abstract 6686: SO-C101 displays strong anti-tumor effect in TC-1 and TRAMP-C2 tumor mice and in combination with PD-1 blockade prevents tumor development in a NK and CD8+ T cells dependent manner
  • Abstract 6678: Sensitive HLA loss of heterozygosity detection reveals allele-specific neoantigen expansion as resistance mechanism to anti-PD-1 therapy
  • Abstract 6644: A comprehensive in vitro and in vivo system to evaluate STING agonist efficacy in cancer therapeutics
Show more Immunology
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement